Pulmonary Arterial Hypertension (PAH) Treatment Market By Drug Class (Endothelin Receptor Antagonists (ERAs), Vasodilators, Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Calcium Channel Blockers (CCBs), Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

The Pulmonary Arterial Hypertension (PAH) Treatment Market Will Exhibit Healthy Growth Between 2018 and 2026.

The global market for pulmonary arterial hypertension (PAH) treatment was worth $7,802.9 million in 2017 and is expected to reach $14,642.1 million by 2026. The global aging population and the rising prevalence of pulmonary arterial hypertension due to risk factors such as connective tissue disorders, HIV infection, chronic liver diseases, lung diseases, sedentary lifestyles, and other idiopathic conditions are driving the market growth. Furthermore, increasing launches of novel drugs and treatment therapies, favorable initiatives by various governments, and rising spending on healthcare are expected to foster market growth over the forecast period. According to the European Respiratory Society (ERS), the global prevalence of PAH ranges from 10 to 52 cases per million and is estimated to be in the range of 100,000–200,000 every year. The Centers for Disease Control and Prevention (CDC) reported that the disease affects 1 to 2 people in every 100,000 people in the U.S. and Europe. This medical condition is more common in older women but can affect men as well. Data published by the National Hospital Discharge Survey and National Vital Statistics System (NVSS) revealed that death rates from PAH increased by 2.5% per year for women and 0.9% per year for men between 2001 and 2010. The World Health Organization (WHO) reported that the global aging population would rise from 841.0 million in 2013 to 962.3 million in 2017 and cross 2 billion by 2050.

Market Synopsis

The Endothelin Receptor Antagonists Segment is expected to continue its dominance over the forecast period from 2018 to 2026.

On the basis of drug class, the endothelin receptor antagonists segment dominated the market in 2017 as endothelin receptor antagonism has emerged as a significant therapeutic strategy that acts as a potential pathogenetic in the development and progression of pulmonary vasculopathy during pulmonary arterial hypertension treatment. Few oral ERs are approved by the U.S. Food and Drug Administration (US FDA) for class III and IV patients suffering from pulmonary arterial hypertension. Letairis/Volibris (ambrisentan), Opsumit (macitentan), and Tracleer (bosentan) are the leading drugs for PAH treatment that support the dominance of ERAs.

Pipeline Analysis: The Presence of Promising Drug Candidates in the Clinical Pipeline Will Be Market Game Changers in the Near Future

Lung Biotechnology PBC (a wholly-owned subsidiary of United Therapeutics Corporation) and Toray Industries, Inc. completed a Phase II extension trial for Beraprost Sodium 314d Modified Release (BPS-314d-MR), a reformulated single isomer of beraprost in PAH patients in the U.S., Ireland, and Belgium. Additionally, on September 3, 2018, Lung Biotechnology PBC planned a Phase III trial for BPS-314d-MR that would be initiated in December 2018. Moreover, Liquidia Technologies, Inc., and Nuventra, Inc., are recruiting for a Phase III clinical trial for LIQ861 (inhaled treprostinil) to evaluate the long-term safety and tolerability of the drug in PAH patients. These pipeline drugs are expected to significantly impact the market by the end of 2020.

North America holds a dominant position due to the presence of supportive infrastructure for the development and distribution of high-quality therapies.

North America held the highest market share in 2017 due to the presence of major market players and well-established healthcare infrastructure, the rising prevalence of lung disorders coupled with increasing US FDA approvals for drugs, and the early market introduction of PAH treatment drugs. On the other hand, a growing elderly population base, along with rising burdens of causative diseases including scleroderma, lupus, cirrhosis of the liver, and HIV infection, and an improving healthcare system in China, India, and Japan, are expected to support the lucrative CAGR of Asia Pacific over the forecast period.

The presence of international market participants makes market penetration challenging for new entrants.

Major players in this space are GlaxoSmithKline plc; Pfizer Inc.; Gilead Sciences, Inc.; Novartis International AG; Bayer AG; Merck KGaA; Bristol-Myers Squibb Company; United Therapeutics Corporation; Actelion Pharmaceuticals Ltd; Reata Pharmaceuticals, Inc.; Toray Industries, Inc.; Liquidia Technologies, Inc.; and Nuventra Pharma Sciences. Companies are focusing on novel drug approvals and launches, mergers and acquisitions, partnerships, and collaboration strategies to gain an impetus in the market. For instance, in November 2015, GlaxoSmithKline plc received approval from the European Commission (EC) for Volibris (ambrisentan) in the treatment of pulmonary arterial hypertension in adult patients of WHO functional class (FC) II to III. In Pfizer Inc.’s Revatio, the capsules containing sildenafil (a phosphodiesterase-5 inhibitor) are used in the treatment of adult patients with PAH.

Periods of History and Forecast

This study report includes an analysis for each segment from 2016 to 2026, with 2017 as the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2018 to 2026.

Report Scope by Segments

The pulmonary arterial hypertension treatment market analyses current market dynamics in both qualitative and quantitative terms. The report involves all-inclusive information on the global pulmonary arterial hypertension treatment market by segmenting the market on the basis of drug class and geography. This report will guide industry investors and associations, pharmaceutical industry participants, venture capitalists, suppliers and distributors of PAH drugs, medical research institutes, research and consulting firms, and healthcare professionals (HCPs) in decision-making and strategizing the market position.

The current report also incorporates qualitative and quantitative analysis of market variables such as key market drivers, restraints, opportunities, and trends, which convey better market information about the entire pulmonary arterial hypertension treatment. Additionally, the report also comprises a graphical illustration of the competitive landscape based on their market initiatives and strategies, product portfolio, financial information, and key developments. Major market players profiled in this study report are GlaxoSmithKline plc; Pfizer Inc.; Gilead Sciences, Inc.; Novartis International AG; Bayer AG; Merck KGaA; Bristol-Myers Squibb Company; United Therapeutics Corporation; Actelion Pharmaceuticals Ltd; Reata Pharmaceuticals, Inc.; Toray Industries, Inc.; Liquidia Technologies, Inc.; and Nuventra Pharma Sciences.

Key questions are answered in this report.

  • What are the current market trends and dynamics in the pulmonary arterial hypertension treatment market, and what are the valuable opportunities for emerging players?
  • Which drug class contributes to the maximum market share?
  • Which drug class accounts for the fastest CAGR during the forecast period?
  • What is the effect of pipeline drugs on market dynamics in the future?
  • What is the impact of high-cost pulmonary arterial hypertension treatment drugs on the market?
  • Are low- and middle-income economies investing in the pulmonary arterial hypertension treatment market?
  • What are the market trends and dynamics in emerging markets such as Latin America, the Middle East, and Africa?

 Frequently Asked Questions:

The market for Pulmonary Arterial Hypertension (PAH) Treatment is expected to reach US$ 14,642.1 Mn in 2026.

The Pulmonary Arterial Hypertension (PAH) Treatment market is expected to see significant CAGR growth over the coming years,at XX%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

GlaxoSmithKline plc,Pfizer Inc.,Gilead Sciences, Inc.,Novartis International AG,Bayer AG are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Sep 2018
Category:  Pharmaceuticals
Report ID:   59330
Report Format:   PDF
Pages:   120
Rating:    4.3 (66)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support